Last reviewed · How we verify
NPH basal insulin titration
NPH basal insulin titration, developed by the University of Malaya, is a marketed product used in the management of diabetes. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | NPH basal insulin titration |
|---|---|
| Sponsor | University of Malaya |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Difference of Basal Insulin Titration Method in Reducing HbA1c Among Type 2 Diabetes Mellitus (T2DM) Patients. (PHASE4)
- Comparison Study of Insulin Glargine and NPH Insulin (PHASE4)
- Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients (PHASE3)
- A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (PHASE3)
- Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (PHASE3)
- Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes (PHASE3)
- Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |